help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on November 15, 2007, doi:10.1164/rccm.200705-675OC

Am. J. Respir. Crit. Care Med., Volume 177, Number 5, March 2008, 544-554

A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200705-675OCv1
177/5/544    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dyugovskaya, L.
Right arrow Articles by Lavie, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dyugovskaya, L.
Right arrow Articles by Lavie, L.

Submitted on May 7, 2007
Accepted on November 15, 2007

Delayed Neutrophil Apoptosis in Sleep Apnea Patients

Larissa Dyugovskaya1, Andrey Polyakov1, Peretz Lavie1, and Lena Lavie1*

1 The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Lloyd Rigler Sleep Apnea Research Laboratory, Unit of Anatomy and Cell Biology, Haifa, Israel

* To whom correspondence should be addressed. E-mail: lenal{at}tx.technion.ac.il.

Rationale: Obstructive sleep apnea (OSA), characterized by Intermittent Hypoxia/Reoxygenation (IHR), is associated with atherosclerosis. Polymorphonuclear leukocytes (PMNs) are implicated in atherogenesis by producing oxidizing radicals and proteolytic enzymes during PMNs/endothelium interactions. PMN apoptosis is a fundamental, injury-limiting mechanism, which prevents their destructive potential. Objective: To determine whether PMN apoptosis and expression of adhesion molecules are affected by OSA and IHR in-vitro. Methods: Apoptosis and expression of adhesion molecules were assessed in whole blood PMNs by flow cytometry, verified by various culture conditions, and morphology. These were complemented by exposing whole blood and PMNs to IHR and to sustained hypoxia in-vitro. Results: This study demonstrates for the first time that in moderate-to-severe OSA patients' PMN apoptosis is delayed. Apoptosis was attenuated in patients with apnea-hypopnea index (AHI)>15, determined by decreased expression of "low-CD16/Annexin-V positive PMNs, by lowered caspase-3 activity and nuclear condensation. Concomitantly, selectin-CD15 expression was increased in a severity dependent manner in moderate-to-severe OSA patients having AHI>15. The percentage of apoptotic PMNs was negatively correlated with OSA severity, determined by AHI, and positively with CD15 expression. In nasal-Continues-Positive-Airway-Pressure (nCPAP) treated patients, CD15 expression was attenuated and "low-CD16" was increased, while omitting nCPAP for a single night increased CD15 expression and decreased the percentage of "low-CD16". IHR In-vitro delayed PMN apoptosis as well. Conclusions: Decreased apoptosis and increased expression of adhesion molecules were noted in OSA PMNs. While adhesion molecules may facilitate increased PMNs/endothelum interactions, decreased apoptosis may further augment these interactions and facilitate free radical and proteolytic enzymes' release.


Key words: obstructive sleep apnea, polymorphonuclear leukocytes, apoptosis, adhesion molecules, atherosclerosis.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
W. T. McNicholas
Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: Overlaps in Pathophysiology, Systemic Inflammation, and Cardiovascular Disease
Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 692 - 700.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S Ryan, C T Taylor, and W T McNicholas
Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?
Thorax, July 1, 2009; 64(7): 631 - 636.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
L. Lavie and P. Lavie
Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link
Eur. Respir. J., June 1, 2009; 33(6): 1467 - 1484.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
M. R. Bonsignore and J. Eckel
Metabolic aspects of obstructive sleep apnoea syndrome
Eur. Respir. Rev., June 1, 2009; 18(112): 113 - 124.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. F. Garvey, C. T. Taylor, and W. T. McNicholas
Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation
Eur. Respir. J., May 1, 2009; 33(5): 1195 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. L. Horner and T. D. Bradley
Update in Sleep and Control of Ventilation 2008
Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 528 - 532.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society
  ATS Quiz on Sleep Study Tracings